Verona Pharma PLC ($VRNA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for respiratory diseases with unmet medical needs. As of February 2025, Ohtuvayre prescriptions have exceeded those in the fourth quarter of 2024. Phase II clinical trials of fixed-dose combinations for bronchiectasis and COPD have been completed. Verona Pharma will continue to market Ohtuvayre in the U.S. and advance Phase II clinical programs.
Buy rating.
Expected target: $90
Weekly Featured Inventory
High-Quality Stocks of the Week for February 7, 2025 ($VRNA)
